Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292055035> ?p ?o ?g. }
- W4292055035 endingPage "100721" @default.
- W4292055035 startingPage "100721" @default.
- W4292055035 abstract "Understanding who is at risk of progression to severe coronavirus disease 2019 (COVID-19) is key to clinical decision making and effective treatment. We study correlates of disease severity in the COMET-ICE clinical trial that randomized 1:1 to placebo or to sotrovimab, a monoclonal antibody for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (ClinicalTrials.gov 04545060). Laboratory parameters identify study participants at greater risk of severe disease, including a high neutrophil-to-lymphocyte ratio (NLR), a negative SARS-CoV-2 serologic test, and whole-blood transcriptome profiles. Sotrovimab treatment is associated with normalization of NLR and the transcriptomic profile and with a decrease of viral RNA in nasopharyngeal samples. Transcriptomics provides the most sensitive detection of participants who would go on to be hospitalized or die. To facilitate timely measurement, we identify a 10-gene signature with similar predictive accuracy. We identify markers of risk for disease progression and demonstrate that normalization of these parameters occurs with antibody treatment of established infection." @default.
- W4292055035 created "2022-08-17" @default.
- W4292055035 creator A5008191609 @default.
- W4292055035 creator A5013572664 @default.
- W4292055035 creator A5020932497 @default.
- W4292055035 creator A5026290406 @default.
- W4292055035 creator A5028808282 @default.
- W4292055035 creator A5029519205 @default.
- W4292055035 creator A5033120989 @default.
- W4292055035 creator A5033355665 @default.
- W4292055035 creator A5034653499 @default.
- W4292055035 creator A5043343236 @default.
- W4292055035 creator A5045359540 @default.
- W4292055035 creator A5045792987 @default.
- W4292055035 creator A5047966663 @default.
- W4292055035 creator A5049148828 @default.
- W4292055035 creator A5049972633 @default.
- W4292055035 creator A5056477151 @default.
- W4292055035 creator A5056972396 @default.
- W4292055035 creator A5061196655 @default.
- W4292055035 creator A5063925347 @default.
- W4292055035 creator A5066398751 @default.
- W4292055035 creator A5067212163 @default.
- W4292055035 creator A5081141710 @default.
- W4292055035 creator A5086492009 @default.
- W4292055035 date "2022-08-01" @default.
- W4292055035 modified "2023-10-18" @default.
- W4292055035 title "Antibody therapy reverses biological signatures of COVID-19 progression" @default.
- W4292055035 cites W2065974896 @default.
- W4292055035 cites W2131271579 @default.
- W4292055035 cites W2137586531 @default.
- W4292055035 cites W2169456326 @default.
- W4292055035 cites W2179438025 @default.
- W4292055035 cites W2191679689 @default.
- W4292055035 cites W2197124664 @default.
- W4292055035 cites W2214074259 @default.
- W4292055035 cites W2532808087 @default.
- W4292055035 cites W2592811885 @default.
- W4292055035 cites W2898598946 @default.
- W4292055035 cites W2945680022 @default.
- W4292055035 cites W3020411887 @default.
- W4292055035 cites W3096658347 @default.
- W4292055035 cites W3111431752 @default.
- W4292055035 cites W3118761697 @default.
- W4292055035 cites W3119134764 @default.
- W4292055035 cites W3125712166 @default.
- W4292055035 cites W3131820551 @default.
- W4292055035 cites W3152551199 @default.
- W4292055035 cites W3164329763 @default.
- W4292055035 cites W3166810840 @default.
- W4292055035 cites W3181759428 @default.
- W4292055035 cites W3193331886 @default.
- W4292055035 cites W3196631202 @default.
- W4292055035 cites W3199962130 @default.
- W4292055035 cites W4205247356 @default.
- W4292055035 cites W4220848096 @default.
- W4292055035 cites W4220886953 @default.
- W4292055035 cites W4220970752 @default.
- W4292055035 cites W4221116249 @default.
- W4292055035 cites W4226004814 @default.
- W4292055035 doi "https://doi.org/10.1016/j.xcrm.2022.100721" @default.
- W4292055035 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35977462" @default.
- W4292055035 hasPublicationYear "2022" @default.
- W4292055035 type Work @default.
- W4292055035 citedByCount "3" @default.
- W4292055035 countsByYear W42920550352023 @default.
- W4292055035 crossrefType "journal-article" @default.
- W4292055035 hasAuthorship W4292055035A5008191609 @default.
- W4292055035 hasAuthorship W4292055035A5013572664 @default.
- W4292055035 hasAuthorship W4292055035A5020932497 @default.
- W4292055035 hasAuthorship W4292055035A5026290406 @default.
- W4292055035 hasAuthorship W4292055035A5028808282 @default.
- W4292055035 hasAuthorship W4292055035A5029519205 @default.
- W4292055035 hasAuthorship W4292055035A5033120989 @default.
- W4292055035 hasAuthorship W4292055035A5033355665 @default.
- W4292055035 hasAuthorship W4292055035A5034653499 @default.
- W4292055035 hasAuthorship W4292055035A5043343236 @default.
- W4292055035 hasAuthorship W4292055035A5045359540 @default.
- W4292055035 hasAuthorship W4292055035A5045792987 @default.
- W4292055035 hasAuthorship W4292055035A5047966663 @default.
- W4292055035 hasAuthorship W4292055035A5049148828 @default.
- W4292055035 hasAuthorship W4292055035A5049972633 @default.
- W4292055035 hasAuthorship W4292055035A5056477151 @default.
- W4292055035 hasAuthorship W4292055035A5056972396 @default.
- W4292055035 hasAuthorship W4292055035A5061196655 @default.
- W4292055035 hasAuthorship W4292055035A5063925347 @default.
- W4292055035 hasAuthorship W4292055035A5066398751 @default.
- W4292055035 hasAuthorship W4292055035A5067212163 @default.
- W4292055035 hasAuthorship W4292055035A5081141710 @default.
- W4292055035 hasAuthorship W4292055035A5086492009 @default.
- W4292055035 hasBestOaLocation W42920550351 @default.
- W4292055035 hasConcept C104317684 @default.
- W4292055035 hasConcept C126322002 @default.
- W4292055035 hasConcept C142724271 @default.
- W4292055035 hasConcept C150194340 @default.
- W4292055035 hasConcept C159654299 @default.
- W4292055035 hasConcept C162317418 @default.
- W4292055035 hasConcept C168563851 @default.